| P/E (FY) | — | Sales (TTM) | $3.2M |
| Earnings (TTM) | -$29.4M | ROE | −169.55% |
| Net Margin | −1817.09% | ROIC | — |
| Debt / Equity | 0.00 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $54.2M | Trading Days | 1247 |
| 52W High | 3.87 |
| 52W Low | 0.44 |
| % Off High | −78.83% |
| YTD | −39.31% | 1Y | 48.69% |
| 3Y | −80.81% | Since incept. (ann.) | −40.33% |
| Ann. Volatility (1Y) | 276.13% | Ann. Volatility (3Y) | 181.02% |
| Sharpe (1Y) | 0.82 | Sharpe (3Y) | 0.25 |
| Max Drawdown (1Y) | −77.80% | Max Drawdown (3Y) | −94.78% |
| Beta (3Y, vs SPY) | 1.29 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CNTX | Context Therapeutics Inc. | $54.3M | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $55.1M | — |
| BOLD | Boundless Bio, Inc. | $55.5M | — |
| XLO | Xilio Therapeutics, Inc. | $52.9M | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $52.7M | — |
| ELTX | Elicio Therapeutics, Inc. | $56.3M | — |
| DWTX | Dogwood Therapeutics, Inc. | $52.1M | — |
| CTOR | CITIUS ONCOLOGY, INC. | $50.3M | — |
| ANVS | Annovis Bio, Inc. | $58.6M | — |
| PMVP | PMV Pharmaceuticals, Inc. | $58.7M | — |
| CING | Cingulate Inc. |
| $60.1M |
| — |
| GOSS | Gossamer Bio, Inc. | $48.1M | — |
